N-(4-((1-Bromonaphthalen-2-yl)oxy)-3-chlorophenyl)-3,5-dichloro-2-hydroxybenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-((1-Bromonaphthalen-2-yl)oxy)-3-chlorophenyl)-3,5-dichloro-2-hydroxybenzamide
• 英文别名: N-[4-(1-bromonaphthalen-2-yl)oxy-3-chlorophenyl]-3,5-dichloro-2-hydroxybenzamide
• 化学式: C₂₃H₁₃BrCl₃NO₃
• 分子量: 537.6
• InChiKey: LLAKCHSBOWDWHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.3
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• PREVENTION AND TREATMENT OF FIBROBLAST GROWTH FACTOR 23 (FGF23)-ASSOCIATED DISORDERS INCLUDING CHRONIC KIDNEY DISEASE (CKD)
  申请人：Veterinärmedizinische Universität Wien

  公开号：EP3403652A1

  公开（公告）日：2018-11-21

  The invention discloses WNK signalling inhibitors, in particular closantel, for use in the prevention and treatment of disorders caused and/or characterized by elevated levels of serum fibroblast growth factor (FGF23), especially chronic kidney disease (CKD). The invention also provides pharmaceutical compositions comprising one/or more WNK signalling inhibitors and methods for use said pharmaceutical compositions in the treatment of subjects diagnosed with FGF23-associated disorders, wherein subjects may be humans and/or companion animals, e.g. dogs and cats.

  本发明公开了WNK信号传导抑制剂，特别是closingantel，用于预防和治疗由血清成纤维细胞生长因子（FGF23）水平升高引起和/或表征的疾病，特别是慢性肾脏病（CKD）。本发明还提供了包含一种和/或多种WNK信号传导抑制剂的药物组合物，以及将所述药物组合物用于治疗被诊断患有FGF23相关疾病的受试者的方法，其中受试者可以是人类和/或伴侣动物，例如狗和猫。
• [EN] PREVENTION AND TREATMENT OF FIBROBLAST GROWTH FACTOR 23 (FGF23)-ASSOCIATED DISORDERS INCLUDING CHRONIC KIDNEY DISEASE (CKD)<br/>[FR] PRÉVENTION ET TRAITEMENT DE TROUBLES ASSOCIÉS AU FACTEUR DE CROISSANCE DES FIBROBLASTES 23 (FGF23), CELA COMPRENANT LA MALADIE RÉNALE CHRONIQUE (MRC)
  申请人：VETERINAERMEDIZINISCHE UNIV WIEN

  公开号：WO2018210449A1

  公开（公告）日：2018-11-22

  The invention discloses WNK signalling inhibitors, in particular closantel, for use in the prevention and treatment of disorders caused and/or characterized by elevated levels of serum fibroblast growth factor (FGF23), especially chronic kidney disease (CKD). The invention also provides pharmaceutical compositions comprising one/or more WNK signalling inhibitors and methods for use said pharmaceutical compositions in the treatment of subjects diagnosed with FGF23-associated disorders, wherein subjects may be humans and/or companion animals, e.g. dogs and cats.